Oxycodone Hydrochloride/Naloxone Hydrochloride Ethypharm (Oxycodone Hydrochloride, Naloxone Hydrochloride Dihydrate)

Oxycodone Hydrochloride, the active ingredient in Oxycodone Hydrochloride/Naloxone Hydrochloride Ethypharm, is a opioid analgesic presented as a controlled‑release tablet for oral use. It is prescribed for managing moderate to severe pain in adult patients when around‑the‑clock relief is required. GNH USA supplies Oxycodone Hydrochloride/Naloxone Hydrochloride Ethypharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Oxycodone Hydrochloride/Naloxone Hydrochloride Ethypharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Oxycodone Hydrochloride/Naloxone Hydrochloride is used in the management of pain through its action on the opioid system.

- Chronic cancer‑related pain: provides sustained analgesia for patients with advanced malignancies. - Severe non‑cancer chronic pain: offers around‑the‑clock relief when other opioids are insufficient. - Post‑operative pain requiring prolonged control: maintains pain control after major surgery when extended therapy is needed.

Side effects are reported across a range of patients using the oxycodone/naloxone combination.

Common Side Effects: - Nausea and vomiting: mild to moderate gastrointestinal upset. - Constipation: reduced bowel motility, though less frequent than with oxycodone alone. - Dizziness or light‑headedness: transient feeling of imbalance. - Dry mouth: reduced salivary flow. - Headache: mild to moderate intensity. - Fatigue: general sense of tiredness.

Serious or Rare Side Effects: - Respiratory depression: slowed breathing that can be life‑threatening. - Severe hypotension: marked drop in blood pressure. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Opioid use disorder: risk of dependence or misuse. - Adrenal insufficiency: rare hormonal imbalance affecting stress response. - Seizures: uncommon neurologic events.

When using this opioid‑antagonist combination, several safety considerations apply.

- Assess pain severity and opioid tolerance: ensure the patient requires strong opioid therapy. - Review medical history for respiratory disorders: patients with COPD or sleep apnea are at higher risk. - Monitor for signs of constipation: despite naloxone, bowel function should be evaluated regularly. - Avoid concurrent CNS depressants: alcohol, benzodiazepines, or other sedatives increase overdose risk. - Adjust dose in renal or hepatic impairment: impaired metabolism may increase drug exposure. - Store at ambient temperature: keep in the original packaging, protect from moisture.

Potential                    ...    ... n  """"  " """ " "  ""  ""  " "  "" " "  ...